Background In Australia, many patients who are initiated on asthma controller inhalers receive combination inhaled corticosteroid/long-acting beta 2 -agonist (ICS/LABA) despite having asthma of sufficiently low severity that ICS-alone would be equally effective and less costly for the government. Methods We conducted a discrete choice experiment (DCE) in a nationally representative sample of adults (n = 792) and parents of children (n = 609) with asthma. Mixed multinomial models were estimated and calibrated to reflect the estimated market shares of ICS-alone, ICS/LABA and no controller. We then simulated the impact of varying patient co-payment on demand and the financial impact on government pharmaceutical expenditure. Results Preference for inhaler decreased with increasing costs to the patient or government, increasing chance of a repeat visit to the doctor, and if fewer symptoms were present. Adults preferred high-strength controllers, but parents preferred low-strength inhalers for children (general beneficiaries only). The DCE predicted a higher proportion choosing controller treatment (89%) compared to current levels (57%) at the current co-payment level, with proportionately higher uptake of ICS-alone and a lower average cost per patient [32.73 Australian dollars (AU$) c.f. AU$38.54]. Reducing the co-payment on ICS-alone by 50% would increase its market share to 50%, whilst completely removing the co-payment would only have a small marginal impact on market share, but increased average cost of treatment to the government to AU$41.04 per person. Conclusions Patient-directed financial incentives are unlikely to encourage much switching of medicines, and current levels of under-treatment are not explained by patient preferences. Interventions directed at prescribers are more likely to promote better use of asthma medicines.
Introduction
Asthma is a chronic, disabling and sometimes fatal inflammatory airways disease that affects millions of children and adults across the globe [1] . The health and economic burden from asthma can be substantially reduced with the consistent use of effective medications, especially inhaled asthma controllers that contain corticosteroids. Inhaled corticosteroids (ICS) are available as a stand-alone product or in a fixed-dose combination product with a long-acting beta 2 agonist (ICS/LABA). However head-to-head studies demonstrate that for both initiation of controller therapy [2] and for stepping up therapy [3, 4] , the majority of benefit arises from the ICS component [2] . International treatment guidelines therefore recommend a stepped approach to therapy, whereby most patients aged 6 years and older should be initiated on ICS-alone, with the use of ICS/ LABA reserved for those whose asthma is uncontrolled despite good adherence and correct inhaler technique with ICS-alone [5, 6] . For children under 6 years, ICS/LABA is not recommended by the national Australian asthma guidelines [6] .
Despite these clinical recommendations, ICS/LABAs are the most common controller treatments for people with asthma in Australia [7] . Both ICS-alone and ICS/LABA are made available to all Australians at subsidised prices via the Pharmaceutical Benefits Scheme (PBS), Australia's national publicly funded universal medicine formulary [8] . The PBS has co-payments for beneficiaries per medicine dispensed, with a maximum co-payment set on the basis of social welfare status (e.g. at the time of the study, concession beneficiaries 6.10 Australian dollars (AU$) and general beneficiaries AU$38.10 per prescription). Once the price of a medicine exceeds the maximum patient copayment, the Australian government pays the remaining cost. As ICS/LABAs are more expensive for the government than ICS-alone, there are potential savings to the government in ICS-alone being used as first-line treatment.
There are many potential levers for changing medication prescription and utilisation patterns, and the use of patient-directed financial incentives has shown much promise. For instance, patients with chronic disease have consistently responded to lower medication co-payments by improving adherence and persistence with effective medications [9] . There is also some evidence that financial incentives, in the form of lower patient co-payments, have a role to play in a patient's initial decision to accept medical treatment, particularly when affordability is a barrier to access [10] . While patient-directed financial incentives for asthma controllers appear to affect patient use [11] , the impact of co-payment on the choice of inhaled asthma controller medication has not been explored.
The success of any financial incentive inherently relies on people being responsive to cost. In Australia, despite medication cost-sharing mechanisms through the PBS, there is evidence that patients stop medications or reduce filling prescriptions when co-payments rise, with asthma controller medications being particularly susceptible [12] . We hypothesised that a financial incentive in the form of a reduced co-payment for ICS-alone may increase overall uptake of controller medicines and decrease the initiation of therapy with ICS/LABA relative to ICS-alone, the more cost-effective option for most people [13] .
Using a discrete choice experiment (DCE) and financial impact analysis, this study sought to estimate the impact on patient preferences for controller inhalers of a financial incentive in the form of a lower co-payment for ICS-alone inhalers for people with asthma, as well as the financial impact on Australian government drug expenditure. DCE is a robust method [14] that has recently been proposed to predict the uptake and substitution patterns of new products upon market entry. By accounting for the influence of product, intervention and user characteristics on user uptake, DCEs can inform modelled cost-effectiveness estimates that traditionally parameterise uptake as linear or are based on expert opinion [15] . Compared to other methods usually employed to answer such questions (e.g. pragmatic randomised controlled trials; quasi-experimental designs using medicine utilisation data), DCEs can generate evidence in a timely fashion relevant for decision-makers and test a wide range of scenarios (including different levels of costs) simultaneously. Importantly, treatment options that may not have been presented to patients, but may indeed be preferred by them if they were a fully informed decision-maker can be explored in a DCE, thus overcoming the issue of "preference misdiagnosis" that pervades clinical practice and secondary data analyses [16] .
Methods

Study Team and Partners
This was an investigator-led partnership study between academics, a national independent advisory group with expertise in primary care clinician/patient engagement regarding healthcare use, and a not-for-profit asthma advocacy group. Collectively, the academics had expertise in health economics and policy research, drug utilisation and pharmacy practice research, general practice research and respiratory medicine research, and population monitoring research. In addition to this core research group, key stakeholders were identified through pre-existing research and professional relationships based on content expertise and especially applicability and use of the outcomes of the research to ensure external validity of the approach taken. This led to the engagement of a consumer representative, clinicians, pharmacists, policy-makers, and representatives of professional colleges and organisations.
Participants
Nationally representative samples of people with asthma and parents of children aged 5-17 years with asthma (based on Australian Bureau of Statistics for people with asthma by age, gender and location) were recruited through an online panel provider (Survey Sample International, Melbourne, Australia) [17] using previously reported methodology [18] . In brief, a three-step randomised selection process was used. First, panel members were selected at random and asked to participate in the survey (topic not identified). Respondents were then asked several profiling questions, including one that asked if they (or their child) had suffered from any of several health issues, including asthma. Those who selected "asthma" were presented with two standard screening questions for current asthma and, if they answered "yes", were eligible to enter the survey. Recruitment was stratified by age, gender and location of residence; of the 1944 participants eligible for survey inclusion, 395 were excluded because their demographic quotas were full, and 148 of the remaining participants did not complete the survey (completion rate 88.2%). Participants received redeemable points to the value of approximately AU$1.50 from the panel provider. Complete data were obtained from 1401 patients (general and concession beneficiaries): 792 adults (age ≥18 years) with asthma and 609 parents of children aged 5-17 years with asthma.
DCE Survey to Assess Patient Preferences for Asthma Controllers
The DCE survey comprised three sections: Sections A and C sought information about participants' sociodemographics (e.g. age, gender, income and location), general health and healthcare utilisation (e.g. co-morbidities), asthma management and symptom control [5] , asthma hospitalisations, medications and asthma medication non-adherence. Section B posed the DCE survey, whereby respondents were asked to answer 12 questions about the choice of hypothetical controller inhalers for initial treatment of asthma. A complete copy of the survey is available from the authors upon request.
DCE Methodology
We followed best practice guidelines in the development, implementation and analysis of our DCE [14] . Respondents were asked to choose between three alternatives: a 1-in-1
controller inhaler representing the ICS-alone inhaler; a 2-in-1 controller inhaler, representing the ICS/LABA inhaler; and no controller. They were provided with brief descriptions of the characteristics of the medicines contained in the 1-in-1 and 2-in-1 medications. We did not label the inhalers with common brand names, to avoid potential bias for or against specific brands or products [19] . The selection of factors and levels for the DCE was based on the findings of qualitative semi-structured interviews among 43 patients and/or parents of children with asthma and was informed by input from key stakeholders within the study team. A list of potential attributes was extracted from the qualitative data, paying close attention to how these attributes and their levels were defined by participants. This initial list was presented to the core research team and reduced by consensus to a list of six to eight attributes based on expert opinion, strength of representation in the qualitative data and potential comprehensibility. The list of attributes was then presented to the broader stakeholder team and further refined based on clinical relevance and plausibility, similarities and differences between controller inhalers on the market, the co-payments required for asthma medicines in Australia, and the cost to the government per person per month for asthma controller inhalers. Further detail about the qualitative study is in Appendix 1 (see the Electronic Supplementary Material). Table 1 lists the factors and levels used in the choice sets. In each choice set, respondents were asked to imagine they were visiting their usual general practitioner (GP) for a routine check-up where they were advised that they (or their child) needed to take controller inhaler every day. In the preamble to the choice questions, participants were provided general information about the two types of controller medicines and the benefits and risks both in the long and short term, and the similarities and differences between the 1-in-1 and 2-in-1 controllers in terms of onset of Chance of revisiting the general practitioner to change the controller 10-80 people per 100 people starting the controller action if the patient was symptomatic at the time he/she was due to take the controller, side effects, frequency of use, and ease of administration. As supported by the literature [2] [3] [4] 20] , the differences in efficacy and side effects between the 1-in-1 and 2-in-1 inhalers were posed as small. The implications of not choosing a controller were also described (e.g. no side effects, but no benefits).
In each choice question, respondents were asked to imagine they were not currently taking a controller and were having asthma symptoms either 1 day per week or less, or 4 days per week or more. On this basis, respondents were then asked to select their preferred option from the two hypothetical medicines or no medicine. Full (rather than partial profiles) were used. An example of a choice task is shown in Fig. 1. 
DCE Survey Design and Piloting
An S-efficient design was generated using NGene software (version 1.1.2; see Appendix 1 in the Electronic Supplementary Material for technical detail). Four survey versions were created: adult (concessional and general beneficiary) and parents of children with asthma (concessional and general beneficiary). Survey versions differed only in terms of the levels of co-payment, to reflect then-current co-payments (i.e. concession AU$6.10 and general AU$38.30) and the patient (i.e. "you" vs "your child").
The online survey was piloted in a 10% panel sample and the results used to update the statistical design. Feedback from the pilot survey indicated that the survey was well understood and easy to complete.
The final updated S-efficient design indicated a minimum required sample size of 197 respondents per version.
Analyses
Using NLOGIT 5.0, mixed (random parameters) multinomial logit models with panel specifications to account for correlated preferences were used to analyse respondent choices. Four discrete choice models were built that assessed the preferences for controller inhaler of patients and parents of children with asthma on the basis of beneficiary status. All models were adjusted for patient clinical and demographic characteristics (see Appendix 2 in the Electronic Supplementary Material for further detail).
Predicting Changes in Demand for Controller Medications with Varying ICS Co-payments
Each DCE model was calibrated to reflect the estimated market shares of ICS-alone, ICS/LABA and "no controller", which were based on actual patient/parent-reported use of these medicines in Sections A and C of the survey [19, 21, 22] . The simulation capability of NLOGIT was then used to estimate changes in market shares [19, 22] for each cohort under the following scenarios: (1) no change to ICS-alone co-payment; (2) 50% reduction in ICS-alone co-payment; and (3) no ICS-alone co-payment. For each simulation, we used the stored parameters estimates from each model and changed the level of co-payment for ICS. We assumed that the cost associated with lowering the ICS co-payment was paid for by a consequent increase in the government contribution. For the ICS/LABA option, co-payment levels were kept constant. Appendix 3 (see the Electronic Supplementary Material) lists the weighted average patient co-payment and government costs for ICS-alone and ICS/LABA that were used in our simulation. As there are multiple ICS-alone and ICS/LABA inhalers in the Australian market, we derived the weighted average cost to the government for ICS-alone and ICS/LABA inhalers from national dispensing data [23] and the market shares of ICS-alone and ICS/LABA reported in the survey. In each simulation, all alternatives were included, and the simulation was applied to all observations in the base case. After each simulation, the impact of each change in ICS co-payment on the choice shares for each alternative was estimated.
Determining the Financial Impact of the Predicted Changes in Market Shares
The predicted changes in market shares for each scenario were applied to the prevalent population of Australian adults and children with asthma, assuming a split across the populations in terms of concessional status as reported in the DCE survey. We derived expenditure based on one prescription per patient rather than incorporating expected adherence over time (see Appendix 3 in the Electronic Supplementary Material for further detail). The changes in the proportion of people on ICS-alone and ICS/LABA and the resultant government expenditure with the three scenarios were compared to the base case comprising the current market shares of ICS-alone, ICS/LABA and no controller as reported by survey participants in the DCE survey. In addition, the cost of controller treatment to the government per patient was estimated. Table 2 lists the demographic and clinical characteristics of the study participants. Overall, participants were similar in age and gender to national data for people with asthma; however, there was over-representation of participants from inner regional Australia and under-representation from outer regional/remote Australia (see Appendix 4 in the Electronic Supplementary Material). Across the four cohorts, respondents were generally well-educated (secondary education or below 24.4-41.4%) and living in households with more than one person with asthma (mean two people per household). Between 27.7 and 39.1% of respondents indicated poor asthma symptom control in the previous month, based on Global Initiative for Asthma (GINA) criteria [5] . In the previous 12 months, 21% of adults and 41% of children had visited an emergency department or were hospitalised for their asthma, and 43% and 60%, respectively, had an urgent visit to a GP for their asthma; however, between 38% and 53% did not report the use of an ICS-containing controller. For adults, the majority on controller treatment were taking an ICS/LABA inhaler; for children, roughly equal proportions of parents reported the child used ICS-alone inhalers or ICS/LABA. Table 3 
Results
Participants
DCE Results
In these models, the beta co-efficient (or preference weight) is a measure of change in preference for a controller inhaler compared to no inhaler as a result of a unit change in a given variable such as out of pocket cost. For the factors that are categorical (e.g. symptoms and strength of inhaler), the co-efficient represents the change in preference when the unit of change is defined as the difference in the full range of categories posed [24] . Across the four cohorts, all attributes were significant, with the exception of product strength and symptom frequency for child concessional beneficiaries. The way in which other factors influenced the choice of inhaler was in the expected direction: preference for inhaler decreased with increasing costs to the patient or government, increasing chance of a repeat visit to the doctor, and if fewer symptoms were present. These results were consistent among adults with asthma and parents of children with asthma, regardless of beneficiary status. Regarding the strength of inhaler, adults with asthma indicated a stronger preference for high-strength asthma inhalers irrespective of beneficiary status. By contrast, low-strength inhalers were preferred for children with asthma (general beneficiary status only). There was marked heterogeneity in preferences for each attribute except for symptom frequency (all cohorts) and product strength (child, concessional), as indicated by non-statistically significant estimated standard deviations for those parameters. On the whole, very few sociodemographic variables had a statistically significant impact on inhaler preference, and associations varied between each cohort (see Appendix 5 in the Electronic Supplementary Material).
While the fit of each model was good, the size of the coefficient of the random alternative specific constants for the 1-in-1 and 2-in-1 inhalers in each cohort were large, with a mean and standard deviation statistically different from zero. This indicates that while there was some heterogeneity over GINA Global Initiative for Asthma, ICS inhaled corticosteroid, LABA long-acting beta 2 -agonist, SD standard deviation a Indicated "yes", often to at least one of four behaviours for asthma medications: delayed due to medication cost, skipped to make it last longer, took fewer puffs to make it last longer, spent less on basic needs to pay for medications as per Madden et al. [34] the sample, on average, participants preferred a controller inhaler over no controller. However, the magnitude of the constant for each alternative within each model was similar, with overlapping confidence intervals. In addition, the models that best fitted the data included generic, as opposed to alternative specific beta coefficients for each factor, indicating that each factor was valued or weighted in the same way for both the 1-in-1 and 2-in-1 alternatives. This suggests that there was no clear preference for the 1-in-1 or 2-in-1 inhaler alternatives as posed in this survey. Table 4 reports the estimated change in market shares for ICS-alone, ICS/LABA and no controller across the three ICS co-payment scenarios, and the estimated financial impact to the government using the current market shares for these agents from participant-reported usage. Without changing the co-payment for ICS-alone, the DCE predicted a higher proportion of the Australian asthma population on controller treatment (89%) compared to the levels reported by patients and parents in the survey (57%), with the majority of that difference resulting from patients taking up an ICS-alone controller (the proportion on ICS-alone would increase from 16% to 43%). This higher proportion of people on controller treatment would be associated with a lower average cost of treatment for the government of AU$32.73 (vs AU$38.54) per patient. This reduction is accounted for by a higher proportion of people on lower cost ICS-alone treatment compared to ICS/LABA. Reducing the ICS-alone co-payment by 50% and 100% increased the market shares for ICS-alone to 50% and 56%, respectively, with the majority of that change attributed to people switching their choice from ICS/LABA inhalers. However, under the assumption that the government would absorb the cost of the co-payment reduction, the cost savings for medicines from this shift would be more than offset by the increased number of people on controller treatment; this would mean that the cost for treatment to the government per asthma patient would increase under both co-payment scenarios to AU$35.88 and AU$41.04, respectively.
Simulated Financial Impact
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Discussion
This study has confirmed that medication co-payment is an important, though not dominant, consideration in the choice of controller inhaler for people with asthma in Australia. It predicted a substantially higher proportion of patients (or parents) preferring to be on controller treatment and also a higher proportion choosing ICSalone inhalers compared to ICS/LABA inhalers, which currently dominate prescribing for adults with asthma in Australia [7, 8, 25] . A financial incentive that lowered the co-payment for ICS-alone had a greater effect in initiating patients on treatment than it did in switching patient choices from ICS/LABA to ICS-alone; such an incentive increased overall costs to the government. These findings suggest that patient-directed financial incentives can encourage patients to take up treatment, but once a prescriber has initiated a course of treatment, such incentives are unlikely to encourage much shift in treatment regimens.
At first glance these findings seem to contradict other research demonstrating the positive impact of lowering patient co-payments on adherence to medications for chronic disease [9] and the impact on adherence of increasing patient co-payments [12] . It is important to recognise that the present study has not investigated the influence of factors including cost on adherence with controller medications for asthma once they have been prescribed, but instead investigated patient/parent choice of treatment at one discrete point in time, when during a routine visit, the GP recommended that the patient should take a regular controller. Indeed, the high proportion of study participants reporting cost-related underuse of controller medication (often referred to as "cost-related nonadherence") over the preceding 12 months (13.9-28.0% of participants often employed one or more cost-related underuse behaviours) demonstrates the influence of cost in this group. This implies that research investigating the impact of a financial incentive on patient medication use needs to view the choice of agent at treatment initiation and the long-term use of the chosen medication as separate levers for influencing the cost-effective use of medications in the community. The marked difference between the proportions of people with asthma expressing a preference for controller treatment in this DCE (89%) compared to those reporting that they had used an ICS-containing controller in the previous 12 months (57%) is noteworthy. While the hypothetical nature of the DCE may be affecting this finding, three other explanations are offered. First, it could reflect the value that people place on their physician recommendation (as described in the DCE scenario), or a lack of perceived autonomy in questioning the treatment choice of prescribers. This is congruent with the apparent reported gatekeeper role of prescribers in treatment selection that emerged in our qualitative research amongst GPs [25] . Further work that can better account for joint agency when using DCEs to predict user uptake is suggested [15, 26] . Second, this finding may point to the existence of preference misdiagnosis, that is, the inability to correctly account for patient preferences in treatment selection [16] . Third, the medicine attributes provided to participants in the DCE introduction were based on evidence from clinical trials [3, 4] , meta-analyses [2] and real-life studies [13] showing modest differences in outcomes with ICS/LABA compared with ICS-alone; this differed from the perceptions of Australian GPs, expressed during qualitative interviews, of a dominant clinical benefit with ICS/LABA [25] .
Nevertheless, these findings expose a number of opportunities for improving the cost-effective use of medications for asthma in contemporary Australian practice. In terms of intervention target, the biggest gains are likely to be achieved by targeting the prescriber. The dominance of ICS/ LABA prescribing in Australia, particularly for adults [18] , is inconsistent with the recommendation in clinical practice guidelines that most asthma patients should be treated with ICS-alone, and it differs substantially from the prescribing pattern in New Zealand, a neighbouring country with a similar public health system, where there were stringent restrictions on prescribing of ICS/LABA for the first 10 years after their introduction [7] . Our interviews also suggested that most GPs were unaware of cost as an important factor for patients [25] . This suggests that encouraging the use of shared decision making in asthma treatment selection, whereby patient preferences for treatment are systematically elicited and addressed, needs further attention. Evidence from Quebec, Canada, has demonstrated the potential for this approach in asthma [27] , as well as other clinical areas. Simply highlighting to patients that they have a choice may be a critical first step.
From a clinical perspective, this study also confirmed that people with asthma are less likely to choose controller therapy over no controller when symptom frequency is comparatively low (1 day per week), although recent evidence shows that, even at this symptom frequency, low-dose ICS-alone halves the risk of serious exacerbations [28] . Furthermore, for adults the perceived higher strength of medication encouraged uptake, perhaps suggesting a perception of greater effects for the costs, whilst for children, lower strength alternatives were preferred, consistent with parental concerns about side effects. Across all cohorts, the need to revisit a physician to change therapy was viewed negatively. While the source of preference heterogeneity within and between cohorts requires further attention through, for instance, the use of latent class modelling, particularly the lack of effect observed relating to product strength and symptom frequency in child concessional beneficiaries, the findings point to the ongoing challenge of implementing guideline-based stepwise therapy for asthma in clinical practice.
Limitations
A number of limitations may affect our results. Hypothetical bias cannot be excluded as with any DCE. We have tried to correct for this by calibrating our models with actual medication use data, explaining to respondents in detail the different clinical implications between choosing treatment and no treatment and using a labelled experiment to improve external and process validity [26, 29, 30] . In addition, we have not modelled adherence and so implicitly assume in the financial modelling that future adherence to ICS-alone and ICS/LABA during ongoing treatment are equivalent, whereas studies have shown an adherence advantage in favour of ICS/LABA [7, 31, 32] . Future work examining the financial impact of these changes over time is needed. While robust qualitative methods were employed in the identification of attributes, this was not in a nationally representative sample, nor did we use established consensus finding techniques (e.g. nominal group or modified Delphi), and we cannot account for the existence of other important attributes. We have assumed that all of the people in our DCE survey and in the population estimates have been correctly diagnosed and that their asthma would be adequately managed on ICS-alone. It is likely that a proportion of these people may be inappropriately diagnosed [33] or may require a step-up to ICS/LABA [5, 6] . In this instance, the magnitude of our financial estimates will be overestimated as well as the extent of people eligible to switch to an ICS-alone controller. Finally, our findings are dependent on the published price of inhalers at the time of the study; any price reductions such as through the introduction of generic versions of ICS/LABA would reduce the financial advantage of ICS-alone therapy.
Conclusions
The current climate sees limited pharmaceutical budgets and a lack of effective financial incentives to prescribe cost-effective treatments. This study has found that a patient-directed financial incentive in the form of lowering ICS-alone copayment relative to ICS/LABA is unlikely to substantially shift the prescribing of ICS/LABA to ICS-alone, the more cost-effective option for most people with asthma. This study has revealed that sufficient financial incentives already exist in the market to promote the use of ICS-alone and so should be exploited. Future efforts to raise the awareness of medication cost to prescribers and to support the incorporation of patient preferences at treatment selection are therefore recommended.
